Terminated PHASE1 INTERVENTIONAL 4-arm NCT01164514

Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant

A Randomized, Partial-Blinded, Placebo-Controlled, Phase I Safety and Immunogenicity Study in Healthy Subjects of Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram Negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions Bacterial Sepsis

Interventions CPG 7909 J5-OMP Vaccine Placebo

Updated 6 times since 2017 Last updated: Jan 30, 2014 Started: Nov 30, 2011 Primary completion: Feb 28, 2013 Completion: Feb 28, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from National Institute of Allergy and Infectious Diseases (NIAID)

See all terminations from National Institute of Allergy and Infectious Diseases (NIAID)

A PHASE1 clinical study on Bacterial Sepsis, this trial is terminated or withdrawn. The trial is conducted by National Institute of Allergy and Infectious Diseases (NIAID) and has accumulated 6 data snapshots since 2011. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Allergy and Infectious Diseases (NIAID)

Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States